WEHI researchers have made a huge leap forward in the fight against Parkinson's disease, solving a decades-long mystery that paves the way for development of new drugs to treat the condition.

Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

A stem cell therapy trial aimed at reducing neuroinflammation in patients with presymptomatic Alzheimer's disease is underway at UTHealth Houston.

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...

The layoffs of thousands of miners in Chiatura, Georgia, ought to be big news in a country of under four million people. But ...